Stalevo® is a combination of levodopa, carbidopa and entacapone. It was initially approved based on pharmacokinetic studies demonstrating bioequivalence with Sinemet® immediate release (IR ...

Carbidopa, levodopa; 25mg/100mg ... May add immediate-release Sinemet 25–100 or 10–100 in advanced disease. Severe cardiovascular or pulmonary disease. Asthma. Renal, hepatic, or endocrine ...

BRIDGEWATER, N.J., April 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today ...

the other half required up to 450 mg/day for levodopa to effectively overcome the effects of inflammation on this dopamine-rich reward circuit. Higher blood levels of CRP indicate increased ...

They were randomized to flexible doses of Stalevo or levodopa/carbidopa IR administered four-times daily on a q3.5 h schedule with a target dose of approximately 400 mg levodopa per day.